TORONTO, Aug. 4, 2008 (PRIME NEWSWIRE) -- Polydex Pharmaceuticals Limited (Nasdaq:POLXF) reports that the final analysis from the Phase III clinical trial of Ushercell, a cellulose sulphate gel developed by Polydex primarily for use by women as a topical contraceptive, was published in the New England Journal of Medicine on July 31, 2008. The Phase III clinical trials were conducted to test Ushercell’s efficacy in prevention of HIV and other sexually transmitted infections. The trials were halted in January 2007 when an independent review of the interim data revealed a higher than expected incidence of HIV in participants at some trial sites.
